Latest Breaking News On - மேத்யூ நீள்வட்டம் - Page 7 : comparemela.com

email article An advisory panel recommended the FDA not revoke the accelerated approval for atezolizumab (Tecentriq) in combination with nab-paclitaxel (Abraxane) for treating metastatic, PD-L1-positive triple-negative breast cancer (TNBC). In a 7-2 vote, the Oncologic Drugs Advisory Committee (ODAC) affirmed the accelerated approval, with members clearly conflicted over the decision. This was a difficult decision in a very difficult disease to treat, said Harold Burstein, MD, PhD, of the Dana-Farber Cancer Institute in Boston, who voted yes on the proposition. I have spent decades caring for these patients, and we all wish we had fundamentally better options. FDA initially granted atezolizumab, a PD-L1 immune checkpoint inhibitor, accelerated approval in 2019 in combination with nab-paclitaxel for patients with untreated metastatic or locally advanced unresectable TNBC whose tumors express PD-L1, based on findings from the IMpassion130 trial, which showed a significant

Dana farber cancer instituteUnited statesBaylor college of medicinePhilip hoffmanHarold bursteinStephen chuiAlberto monteroLaleh amiri kordestaniMatthew ellisStanley lipkowitzGenentech group medical directorNational cancer institute in bethesdaOncologic drugs advisory committeeUniversity of chicagoDivision of oncologyCase western reserve university in cleveland